17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Xarelto
Posted at 12:50h
in
Important safety information on the treatment of patients with antiphospholipid syndrome (APS) and the use of rivaroxaban (Xarelto®) Possible increased risk for recurrent thrombotic events
2019 Aug
Download latest version
File Type:
pdf
Category:
Communication To Health Care Professionals